TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21315216
Drug: CCM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCM plus optimal medical therapy (OMT)
Study: 18990434
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin with 150 mg clopidogrel
Study: 18990434
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg aspirin with 150 mg clopidogrel
Study: 15526839
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (200 IU, thrice a week)
Study: 15526839
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (up to 6 g/d) alone or with aluminum hydroxide (up to 3 g/d) as phosphate binders
Study: 1616360
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin
Study: 2936636
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1% isoconazole nitrate in the morning followed in the evening by 5% benzoyl peroxide
Study: 20384968
Drug: SR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR oxycodone
Study: 12424549
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oxazepam
Study: 24293756
Drug: Vestipitant (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestipitant (15 mg)
Study: 17009541
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese medicine with massage
Study: 17009541
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese medicine only
Study: 28403910
Drug: Jaungo applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jaungo applied twice a day for 3 weeks
Study: 23307204
Drug: CC‐IFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐IFA
Study: 12940868
Drug: Mix25 twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix25 twice daily (Mix25 before both breakfast and evening meal)
Study: 11130522
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (n=12,699)
Study: 11130522
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drugs (n=15,044)
Study: 24123134
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 at 200 IU/day (low dose)
Study: 24123134
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 at 2000 IU/day (high dose)
Study: 22045128
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg at the corrugator supercilii muscle
Study: 22045128
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg at the orbicularis oris muscle
Study: 22045128
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg at the orbicularis oris and corrugator supercilii muscles
Study: 2979691
Drug: Placebo preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation
Study: 27624173
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg Bevacizumab plus 300 µg/0.1 mL Diclofenac (IVB/D)
Study: 27624173
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravitreal Bevacizumab (IVB)
Study: 25445103
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of EMLA (lidocaine-prilocaine cream)
Study: 25445103
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of placebo
Study: 19225139
Drug: Folate and
Normalized name: Folate and/or folate derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate and betaine treatment
Study: 8907095
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of nicotine polacrilex
Study: 7594291
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection with lidocaine
Study: 2329813
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with total triterpenic fraction of Centella asiatica (60 mg twice daily for 7 days)
Study: 6990745
Drug: Inhalation isoetharine
Normalized name: isoetharine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation isoetharine hydrochloride
Study: 31276265
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate (MF) cream + LA‐Cer‐containing moisturizer
Study: 29726361
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate (MF) cream
Study: 28142364
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy (Control)
Study: 21208922
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of varicella vaccine
Study: 19046724
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg/day
Study: 15310086
Drug: Megamin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megamin (3.6 g daily for 6 to 8 weeks)
Study: 15310086
Drug: Lycopenomin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopenomin (1.2 g daily for 6 to 8 weeks)
Study: 12520630
Drug: ReN1869 (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReN1869 (3.5 to 95 mg)
Study: 2528841
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg t.i.d. for 1 month, 40 mg t.i.d. thereafter; n = 63 patients)
Study: 756476
Drug: Brief psychotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychotherapy and behavior therapy
Study: 28851088
Drug: ALA-DAG (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-DAG (2.5 g/d for 12 weeks)
Study: 20615317
Drug: Rush build-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush build-up schedule with Depigoid-SCIT (0.2 mL on day 1, 0.3 mL on day 1, 0.5 mL on day 28)
Study: 16170235
Drug: Flunitrazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (6 mg/70 kg)
Study: 16170235
Drug: Triazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (1 and 2 mg/70 kg)
Study: 8542104
Drug: Azelastine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 6 mg twice per day
Study: 1922236
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with cyclophosphamide, methotrexate, and fluorouracil
Study: 1922236
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no further treatment) followed by reinduction therapy with cyclophosphamide, methotrexate, and fluorouracil
Study: 1922236
Drug: Reinduction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction therapy with cyclophosphamide, methotrexate, and fluorouracil
Study: 1922236
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival for maintenance therapy group
Study: 6405607
Drug: Copper supplement
Normalized name: Copper supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplement (80 micrograms/kg/day as sulphate)
Study: 23661044
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (2.5 mg/0.1 mL)
Study: 16891588
Drug: 17-mg hydrocortisone
Normalized name: Hydrocortisone 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17-mg hydrocortisone
Study: 17542944
Drug: Melatonin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1.5 mg)
Study: 10910871
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg melatonin
Study: 17122221
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg melatonin
Study: 31190751
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg midazolam
Study: 1313637
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg twice a day for 10 days
Study: 1313637
Drug: Amoxicillin/probenecid or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/probenecid or doxycycline extended treatment if symptoms were still present at 10 days
Study: 1313637
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effectiveness of the three regimens
Study: 17208082
Drug: Long-term low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term low-molecular-weight heparin (LMWH) therapy (tinzaparin)
Study: 17208082
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (vitamin K antagonist therapy)
Study: 31522334
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment 0.03%
Study: 11524191
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine hydrochloride 2%
Study: 9627287
Drug: Salpingectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salpingectomy followed by IVF with combined GnRH agonist and hMG therapy
Study: 31928931
Drug: Multivalent HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors
Study: 20078487
Drug: Pregabalin (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (450 mg/day)
Study: 10193230
Drug: EMLA patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA patch
Study: 30552275
Drug: Chocolate containing
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate containing 99% cocoa, 10g daily for 6 months
Study: 25163019
Drug: Valacyclovir 1
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1 g twice daily
Study: 10102256
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg/day
Study: 12421835
Drug: Maternal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vitamin A supplementation (60 mg retinol palmitate at 18-42 days postpartum)
Study: 12421835
Drug: Infant vitamin
Normalized name: Leader Infant Vitamin D 400 International Units/mL Drops (Cherry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant vitamin A supplementation (7.5 mg at 6, 10, and 14 weeks of age)
Study: 10592404
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS), given once daily for 1 week
Study: 31724501
Drug: Chlorhexidine brush-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine brush-on gel
Study: 21576473
Drug: NVP-containing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP-containing treatment arm
Study: 21576473
Drug: lopinavir/ritonavir-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir-containing treatment arm
Study: 11314153
Drug: Onerous procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Onerous procedures (such as intramuscular injections)
Study: 8001531
Drug: Drink A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink A (90 mmol.l-1 glucose solution)
Study: 8001531
Drug: Drink B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink B (60 mmol.l-1 sodium chloride)
Study: 28692122
Drug: IL-18 gene
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-18 gene polymorphisms -656 G/T and -607 C/A
Study: 28327988
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg twice daily
Study: 2864221
Drug: Beta 2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2‐agonist therapy alone
Study: 2864221
Drug: Beta 2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2‐agonist therapy in combination with theophylline
Study: 2864221
Drug: Beta 2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2‐agonist therapy in combination with enprofylline
Study: 31138577
Drug: Cefoperazone-sulbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone-sulbactam (2 g of each per 12 h)
Study: 31138577
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g per 12 h)
Study: 27840383
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg/day
Study: 27840383
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg/day (switch from sitagliptin)
Study: 15289793
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin for 10 days
Study: 11410117
Drug: Low-sodium (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium (50 mmol/day), low-nitrate (400 micromol/day) diet supplemented with NaCl tablets (200 mmol/day) for 7 days
Study: 9240301
Drug: Heparin-coated extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated extracorporeal circuit (n = 15)
Study: 8317868
Drug: Reperfusion solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion solution
Study: 29054128
Drug: Combination varenicline/bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination varenicline/bupropion treatment
Study: 23782896
Drug: Roux-en-Y gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y gastric bypass (RYGB) with standardized medical treatment if needed
Study: 23782896
Drug: Standardized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized medical treatment (control group)
Study: 16766775
Drug: Combination high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination high FV, low-fat intervention
Study: 15528909
Drug: High-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sodium fluoride dentifrice (2,800 ppm F, high-NaF)
Study: 3429174
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) glucagon
Study: 15738750
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg modafinil
Study: 17603048
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg once daily with brief lifestyle modification
Study: 17115902
Drug: HCV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV therapy
Study: 12663719
Drug: Oxaliplatin 130
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m² day 1 plus capecitabine 2,000 mg/m²/d days 1 to 14 every 3 weeks (arm A)
Study: 12663719
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m² days 1 and 14 combined with capecitabine 3,500 mg/m² days 1 to 7 and 14 to 21 every 4 weeks (arm B)
Study: 31909703
Drug: Typical physical
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical physical therapy (Control)
Study: 31226660
Drug: Subliminal intragastric
Normalized name: ALCOHOL 80 mL in 100 mL INTRAGASTRIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subliminal intragastric infusion of 2.5 g lauric acid
Study: 26859547
Drug: 0.4 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 μg/kg dexmedetomidine (small dose)
Study: 26859547
Drug: 0.8 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 μg/kg dexmedetomidine (medium dose)
Study: 24078278
Drug: DA-3031 (1.8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-3031 (1.8, 3.6, 6, or 18 mg)
Study: 24078278
Drug: DA-3031 (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-3031 (3.6 to 6 mg)
Study: 24078278
Drug: Filgrastim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (100 μg/m² daily for 5 days)
Study: 17012110
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of serum bFGF levels with FSH administration
Study: 10981170
Drug: Candesartan cilexitil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexitil (angiotensin receptor blocker)
Study: 27983687
Drug: Whole barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole barley flour (48 g)
Study: 22936658
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CT) with lenalidomide and rhu-EPO (40,000 U/wk)
Study: 8963958
Drug: Systemically ineffective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically ineffective dose of AII
Study: 8963958
Drug: Systemically effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically effective dose of AII
Study: 27503091
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (400 mg/day)
Study: 23647356
Drug: 2% Chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Chlorhexidine digluconate gel (CHX)
Study: 23647356
Drug: Chemomechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical preparation with 3% sodium hypochlorite (NaOCl)
Study: 22882916
Drug: Amoxicillin‐clavulanate +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate + ciprofloxacin (250 mg; one dose before and two doses after biopsy)
Study: 16024926
Drug: High-dose citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose citric acid-based UBT at 14 days after triple therapy
Study: 16024926
Drug: High-dose citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose citric acid-based UBT at 7 days after triple therapy
Study: 16024926
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard UBT at 6 weeks after therapy
Study: 23146246
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg
Study: 12601506
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg plus Cyproheptadine 4 mg
Study: 12601506
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg plus Cyproheptadine 4 mg
Study: 10365576
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (interferon-alpha 2b) for 6 months
Study: 8660081
Drug: Colestipol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (10 g/day)
Study: 1826048
Drug: ZOLADEX (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOLADEX (3.6 mg every 28 days by subcutaneous injection)
Study: 1826048
Drug: DES (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES (3 mg daily by oral administration)
Study: 16029995
Drug: Calcium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel blockers (CCB)
Study: 16029995
Drug: Irbesartan, ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan, ACE inhibitors, CCB
Study: 8559949
Drug: Continuation light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation light treatment until late winter (n = 8)
Study: 2706319
Drug: Research Suspension
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research Suspension (RS)
Study: 2706319
Drug: Reference Oral
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference Oral Solution (SOL)
Study: 2706319
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (MS, RS, SOL)
Study: 29668611
Drug: Sham intradermal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intradermal needle
Study: 29668611
Drug: Intradermal needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needle
Study: 18454914
Drug: 3.5% solution
Normalized name: Aminosyn 3.5% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% solution of betadine irrigation before final closing of the wound (Group 1)
Study: 8737690
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg orally TID for 3 days preoperatively and 300 mg infusion after anesthetic induction
Study: 24509273
Drug: Evolocumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (AMG 145) 140 mg every 2 weeks
Study: 24509273
Drug: Evolocumab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (AMG 145) 420 mg every 4 weeks
Study: 15616296
Drug: Telavancin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 7.5 mg/kg/day
Study: 15616296
Drug: Telavancin 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 12.5 mg/kg/day
Study: 15616296
Drug: Telavancin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 15 mg/kg/day
Study: 15616296
Drug: Telavancin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (multiple doses)
Study: 12062586
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of M. officinalis (Pharmaton)
Study: 12062586
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of M. officinalis (Pharmaton)
Study: 12062586
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of M. officinalis (Pharmaton)